CoreValve, Inc. Announces Successful Completion of Initial Series of Proctored Cases in Australia and New Zealand Using Its ReValving(R) System for Percutaneous Aortic Valve Replacement

IRVINE, Calif.--(BUSINESS WIRE)--CoreValve (www.corevalve.com) announced today that five (5) clinical evaluation sites—two in New Zealand and three in Australia—have now completed their first series of proctored cases using the Company’s proprietary ReValving® System for percutaneous aortic valve replacement (PAVR), which features a porcine pericardium valve mounted in a self-expanding frame.